Analytical Data
-
Gene name
KDM4A
- Application
-
Alternative Names
JMJD2; JMJD2A; JHDM3A; JmjC domain-containing histone demethylation protein 3A; Jumonji domain-containing protein 2A
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75164
-
Expression Region
Tyr141~Lys310
-
Molecular Weight
23kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KDM4A, a member of the lysine-specific demethylase (KDM) family, plays a crucial role in the regulation of gene expression through its enzymatic activity that demethylates lysine residues on histones, particularly H3K9me3 and H3K36me3. This demethylation process is essential for maintaining normal cellular functions, including cell cycle progression and differentiation. Aberrant expression or mutations in KDM4A have been implicated in various cancers, emphasizing the significance of understanding its functional mechanisms. Additionally, KDM4A is involved in several biological processes such as DNA damage response and transcriptional regulation, making it a potential target for cancer therapy. Recent studies have focused on the structural analysis and the development of small-molecule inhibitors to modulate KDM4A activity, further highlighting its therapeutic potential. With the increasing interest in epigenetic modulation as a strategy for cancer treatment, KDM4A-recombinant proteins are being utilized as tools for investigating its biochemical properties and interactions, paving the way for novel approaches in the field of epigenetics and oncology.
